Form 4: Ionis Pharmaceuticals Director Joan E. Herman Reports Stock Acquisition Through Restricted Stock Unit Vesting

Director Joan E. Herman acquired 4,677 shares of Ionis Pharmaceuticals common stock on July 15, 2024, through the vesting of restricted stock units.

Summary

• On July 15, 2024, Joan E. Herman, a director of Ionis Pharmaceuticals, acquired 4,677 shares of common stock.
• The acquisition was a result of the vesting of restricted stock units (RSUs).
• Each RSU represents the right to receive one share of Ionis common stock or its equivalent cash value.
• Following the transaction, Herman directly owns 42,007 shares of Ionis Pharmaceuticals.
• Herman also owns 4,079 derivative securities in the form of Restricted Stock Units.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects a routine transaction related to executive compensation. There are no explicit positive or negative implications for the company's performance.

Positives

• The vesting of RSUs indicates that Herman has met certain performance or time-based requirements set by Ionis Pharmaceuticals.
• Increased share ownership aligns Herman's interests with those of other shareholders.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, such as directors, who trade in their company's stock. It provides transparency to the market regarding insider transactions.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders, as it is a standard part of executive compensation.

Key Dates